Systemic chemotherapy including ramucirumab in combination with pressurized intra-peritoneal aerosol chemotherapy (PIPAC) is a safe treatment option for peritoneal metastasis of gastric cancer

2021 ◽  
Vol 47 (2) ◽  
pp. e26
Author(s):  
Linda Feldbrügge ◽  
Felix Gronau ◽  
Andreas Brandl ◽  
Timo Alexander Auer ◽  
Maximilian Jara ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Treatment Option ◽  
Peritoneal Metastasis ◽  
Systemic Chemotherapy ◽  
Safe Treatment ◽  
Safe Treatment Option

scholarly journals Systemic Chemotherapy Including Ramucirumab in Combination With Pressurized Intra-Peritoneal Aerosol Chemotherapy Is a Safe Treatment Option for Peritoneal Metastasis of Gastric Cancer

2021 ◽  
Vol 10 ◽  
Author(s):  
Linda Feldbrügge ◽  
Felix Gronau ◽  
Andreas Brandl ◽  
Timo Alexander Auer ◽  
Alan Oeff ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systemic Therapy ◽  
Peritoneal Metastasis ◽  
Systemic Chemotherapy ◽  
Postoperative Morbidity ◽  
Laparoscopic Technique ◽  
Complication Rates ◽  
The Mean ◽  
Safe Treatment Option ◽  
Length Of Interval

BackgroundPressurized intraperitoneal aerosol chemotherapy (PIPAC) is a laparoscopic technique for local chemotherapy. It has been used for treatment of peritoneal metastasis of gastric cancer (PM GC) in combination with systemic therapy. VEGFR2 antagonist ramucirumab is a second-line therapy for GC, and has been suspected to cause wound healing disorders.MethodsThis is a retrospective single center cohort study of patients with PM GC, who received PIPAC treatment in combination with systemic chemotherapy with and without ramucirumab. Data on patients’ characteristics and their perioperative courses were collected and complication rates were compared with regard to preoperative use of ramucirumab and time between last dose of systemic therapy and PIPAC treatment.ResultsFifty patients underwent 90 PIPAC treatments for PM GC in 3 years. Overall postoperative morbidity was 11% with 6% severe complications. The mean interval between systemic therapy and PIPAC was 20 days. Neither the length of interval nor the use of ramucirumab had an effect on complication rates.ConclusionOur study suggests that addition of ramucirumab to pre-PIPAC systemic therapy, irrespective of the length of the treatment-free interval before PIPAC, does not increase the risk of postoperative complications and is therefore a safe option for treatment of PM GC.

scholarly journals A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy

Blood ◽  
2017 ◽  
Vol 130 (9) ◽  
pp. 1097-1103 ◽  
Author(s):  
Zhangyuan Kong ◽  
Ping Qin ◽  
Shan Xiao ◽  
Hai Zhou ◽  
Hong Li ◽  
...  
Keyword(s):  
Treatment Option ◽  
Immune Thrombocytopenia ◽  
Safe Treatment ◽  
Key Points ◽  
Safe Treatment Option ◽  
Recombinant Human Thrombopoietin ◽  
In Pregnancy

Key Points rhTPO is a potentially effective and safe treatment option for ITP during pregnancy.

Bidirectional Systemic Chemotherapy and Pressurized Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis from Gastric Cancer

2020 ◽  
Vol 46 (2) ◽  
pp. e139
Author(s):  
Andrea Di Giorgio ◽  
Stefano Rotolo ◽  
Carlo Abatini ◽  
Miriam Attalla El Halabieh ◽  
Antonia Strippoli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Metastasis ◽  
Systemic Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document